Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Silence Therapeutics PLC

Healthcare US SLN

6.41USD
0.04(0.63%)

Last update at 2026-06-03T20:00:00Z

Day Range

6.196.79
LowHigh

52 Week Range

4.8427.72
LowHigh

Fundamentals

  • Previous Close 6.37
  • Market Cap1030.72M
  • Volume119841
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-49.27200M
  • Revenue TTM25.38M
  • Revenue Per Share TTM0.68
  • Gross Profit TTM 6.62M
  • Diluted EPS TTM-1.18

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -47.36800M -45.85600M -36.04100M -22.87000M -20.52600M
Minority interest - - - - -
Net income -40.48900M -39.41000M -32.54700M -19.58200M -18.41100M
Selling general administrative 19.61M 20.01M 13.98M 9.64M 10.83M
Selling and marketing expenses - - - - -
Gross profit 6.62M 4.96M 1.72M 0.24M -
Reconciled depreciation 0.48M 0.43M 0.50M 0.48M 0.40M
Ebit -48.59300M -45.81400M -35.84700M -22.73400M -20.57100M
Ebitda -47.88500M -45.37700M -35.22200M -22.22500M -20.17200M
Depreciation and amortization 0.71M 0.44M 0.62M 0.51M 0.40M
Non operating income net other - - - - -
Operating income -48.59300M -45.81400M -35.84700M -22.73400M -20.57100M
Other operating expenses 66.09M 58.23M 41.33M 22.98M 20.57M
Interest expense 0.05M 0.00800M 0.32M 0.16M 0.04M
Tax provision -6.87900M -6.44600M -4.60000M -3.28800M -2.11500M
Interest income 0.23M 0.01000M 1.73M 0.03M 0.04M
Net interest income 0.18M 0.00200M 1.73M -0.00600M 0.04M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -6.87900M -6.44600M -3.49400M -3.28800M -2.11500M
Total revenue 17.50M 12.41M 5.48M 0.24M 0.00000M
Total operating expenses 55.21M 50.77M 37.56M 22.98M 20.57M
Cost of revenue 10.88M 7.46M 3.76M - -
Total other income expense net 1.23M -0.04200M -0.19400M -0.13600M 0.00600M
Discontinued operations - - - - -
Net income from continuing ops -40.48900M -39.41000M -22.05800M -19.58200M -18.41100M
Net income applicable to common shares -40.48900M -39.41000M -32.54700M -19.58200M -18.41100M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 93.82M 107.50M 96.19M 85.97M 46.08M
Intangible assets 0.28M 0.32M 0.02M 0.02M 0.03M
Earning assets - - - - -
Other current assets 26.76M - 4.31M 4.62M 0.89M
Total liab 76.77M 85.43M 87.67M 76.91M 25.17M
Total stockholder equity 17.05M 22.07M 8.53M 9.06M 20.91M
Deferred long term liab - - - - -
Other current liab 9.80M 9.45M 6.72M 5.91M 5.10M
Common stock 5.94M 5.39M 4.49M 4.17M 3.92M
Capital stock 5.94M 5.39M 4.49M 4.17M 3.92M
Retained earnings -304.61200M -263.26300M -222.96600M -184.21500M -151.99900M
Other liab - 63.48M 72.50M 51.34M 15.52M
Good will 7.84M 8.01M 7.59M 8.12M 7.69M
Other assets - - - - -
Cash 54.03M 54.82M 73.54M 27.45M 13.52M
Cash and equivalents - - - - -
Total current liabilities 17.77M 21.94M 15.17M 25.57M 9.65M
Current deferred revenue 5.16M 8.86M 4.25M 17.04M 2.48M
Net debt -53.75900M -54.37000M -73.40000M -27.10800M -13.22800M
Short term debt 0.18M 0.45M 0.14M 0.34M 0.29M
Short long term debt - - - - -
Short long term debt total 0.27M 0.45M 0.14M 0.34M 0.29M
Other stockholder equity 291.52M 255.61M 203.21M 9.06M 171.94M
Property plant equipment - 2.20M 1.94M 1.13M 0.61M
Total current assets 81.02M 96.69M 86.33M 76.40M 37.47M
Long term investments 0.28M 0.28M 0.30M 0.30M -
Net tangible assets - 13.74M 0.91M 0.92M 13.18M
Short term investments 0.00000M 16.33M - 10.00M 20.00M
Net receivables 18.83M 17.34M 8.49M 32.84M 3.06M
Long term debt - - - - -
Inventory -18.60500M - - 1.49M -
Accounts payable 2.63M 3.19M 4.07M 8.19M 6.89M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 24.20M 24.33M 23.79M 189.11M 168.99M
Additional paid in capital - - - - -
Common stock total equity - - - 4.17M 3.92M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.58M - - 10.00M 20.00M
Deferred long term asset charges - - - - -
Non current assets total 12.80M 10.81M 9.86M 9.57M 8.61M
Capital lease obligations 0.27M 0.45M 0.14M 0.34M 0.29M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -16.54200M 10.00M -41.25400M -15.01500M -4.83000M
Change to liabilities -3.45400M 10.77M 51.69M 21.05M 1.15M
Total cashflows from investing activities -16.54200M 8.68M 9.62M -15.01500M -4.83000M
Net borrowings -0.19000M -0.21100M -0.40200M -0.40200M -0.40200M
Total cash from financing activities 43.05M 30.71M 15.43M 5.27M 0.34M
Change to operating activities -4.22500M 0.59M -3.73000M 0.04M -0.92400M
Net income -47.36800M -45.85600M -36.04100M -22.87000M -20.52600M
Change in cash -18.72100M 46.09M 13.93M -7.97900M -21.25100M
Begin period cash flow 73.54M 27.45M 13.52M 21.49M 42.74M
End period cash flow 54.82M 73.54M 27.45M 13.52M 21.49M
Total cash from operating activities -45.45600M 6.81M -10.77600M 1.73M -16.76000M
Issuance of capital stock 43.24M 30.92M 15.83M 5.27M 0.34M
Depreciation 0.48M 0.43M 0.50M 0.48M 0.40M
Other cashflows from investing activities 0.02M 0.01000M 0.13M -0.00600M 0.04M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.58400M 27.48M -29.30200M -0.00400M 0.69M
Sale purchase of stock - - - - 0.00000M
Other cashflows from financing activities -16.54200M 8.68M 9.62M -15.01500M -4.83000M
Change to netincome 2.81M 6.94M 7.48M -0.25800M 0.34M
Capital expenditures 0.44M 1.33M 0.51M 0.00900M 0.19M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -8.26300M 38.84M 18.66M 21.09M 0.91M
Stock based compensation 10.25M 8.63M 4.39M 0.58M 0.68M
Other non cash items -0.55900M 0.35M -4.67000M 0.14M -0.04500M
Free cash flow -45.89600M 5.47M -11.29000M 1.72M -16.94800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SLN
Silence Therapeutics PLC		 0.04 0.63% 6.41 - - 43.41 48.26 40.77 -20.7846
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Silence Therapeutics PLC

72 Hammersmith Road, London, United Kingdom, W14 8TH

Key Executives

Name Title Year Born
Mr. Craig A. Tooman M.B.A., MBA Pres, CEO & Exec. Director 1966
Ms. Rhonda L. Hellums Chief Financial Officer 1972
Dr. Giles V. Campion M.D. Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director 1954
Ms. Gem Gokmen Hopkins Head of IR & Corp. Communications NA
Dr. John Strafford Ph.D. Sr. VP of Bus. Devel., Alliance Management & New Product Devel. NA
Mr. Jørgen Wittendorff Sr. VP & Head of Manufacturing NA
Dr. Barbara A. Ruskin J.D., Ph.D. Sr. VP and Chief Intellectual Property & Innovation Officer 1960
Dr. Eric Floyd Ph.D. Sr. VP of Regulatory Affairs & Quality Assurance 1962
Dr. Marie Wikstrom Lindholm Ph.D. Sr. VP & Head of Molecular Design NA
Mr. Craig A. Tooman M.B.A. President, CEO & Executive Director 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions